Search

The extracellular matrix molecular collagen is the one of the most widely utilized scaffolding materials in tissue engineering. However, obtaining uniform bioactive collagen films in the nanoscale range and precisely controlling the physical and chemical properties of these biological films is still a challenge for biomedical engineering. Layer-by-layer assembly, i.e., sequential adsorption of oppositely charged macromolecular species, is a powerful new film preparation technique that can be applied to the design of versatile biomaterials, with well-controlled interfacial, mechanical and biological functions. To demonstrate the feasibility of biomaterial design by means of layer-by-layer assembly, type-I collagen thin films were prepared by using this technique with poly(styrene) sulfonate as a partner polyelectrolyte. The gradual build-up of the collagen films was confirmed by UV-vis spectroscopy and ellipsometry, while their surface morphology was assessed by atomic force microscopy. The thickness of the collagen layers can be changed by increasing the number of bilayers adsorbed with an increment of 13 nm. It was found that the layer-by-layer assembled collagen scaffolds can support the attachment and growth of C2C12 myoblast cells and PC12 pheochromocytoma cells. Accurate thickness control and compatibility with nerve cell precursors indicate the utility of layer-by-layer assembled films in neuroprosthesis.

Background The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, results with N-terminal inhibitors from initial clinical trials have been disappointing, as toxicity and resistance resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns. Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for the treatment of prostate cancer. Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described, which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel approach to characterize Hsp90 inhibition in cancer cells. Methods PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect in vitro Hsp90 inhibition assays (DARTS, Surface Plasmon Resonance, co-immunoprecipitation, luciferase, Western blot, anti-proliferative, cytotoxicity and size exclusion chromatography) to characterize the effects of KU174 in prostate cancer cells. Pilot in vivo efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies. Results KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degradation and disruption of Hsp90 native complexes without induction of a HSR. Furthermore, KU174 demonstrates direct binding to the Hsp90 protein and Hsp90 complexes in cancer cells. In addition, in pilot in-vivo proof-of-concept studies KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model. Conclusions Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for the treatment of prostate cancer.